Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMeridian Lyfgenia (lovotibeglogene) Coverage Updat…
    Ask Trek AI about this page
    CurrentmeridianPolicy MDN.CP.PHAR.627

    Lovotibeglogene autotemcel (Lyfgenia) gene therapy coverage

    Customize your policy alerts

    Sign up for meridian Policy MDN.CP.PHAR.627 alerts

    Get alerted when Policy MDN.CP.PHAR.627 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, authorization, and coverage criteria for Lyfgenia (lovotibeglogene autotemcel) for members (Medicaid line of business) including initial and continuation criteria and documentation requirements for providers.

    Policy Summary
    Payermeridian
    PolicyLovotibeglogene autotemcel (Lyfgenia) gene therapy coverage
    Policy CodePolicy MDN.CP.PHAR.627
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewJan 2, 2026
    Next Review Date
    Key ActionPrior authorization requires PDAC review and submission of clinical documentation that all approval criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥12 yrsmin age
    ≥3×10^6min CD34+ dose
    One-timedosing frequency
    12 monthsapproval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥4 VOEs
    VOE eligibility
    J3394HCPCS code

    Coverage Criteria for Lyfgenia (lovotibeglogene autotemcel)

    Initial Therapy - Sickle Cell Disease

    Covered when ALL of the following are met for SCD:

    SCD Initial Approval: 1. Diagnosis of sickle cell disease (SCD).
    Genetic confirmation: 2. Genetic testing confirming sickle cell disease.
    Age: 3. Age ≥ 12 years at time of gene therapy administration.≥12 years
    VOE or transfusion criteria: 4. Provider attestation of one of the following: a) ≥4 vaso-occlusive events (VOE) in the past 24 months while receiving appropriate standard of care; OR b) currently receiving chronic transfusion therapy for recurrent vaso-occlusive events.
    Hydroxyurea failure/intolerance: 5. Failure or intolerance to hydroxyurea (unable to take hydroxyurea per clinician judgment) at any point in the past.
    HSCT eligibility: 6. Prescriber attestation that participant is clinically stable and eligible to undergo hematopoietic stem cell transplantation (HSCT).
    Prescriber specialty: 7. Medication prescribed by or in consultation with a board-certified hematologist or transplant specialist experienced in the treatment of patients with SCD.
    Dose requirement: 8. Dose contains a minimum of 3 × 10^6 CD34+ cells/kg.≥3×10^6 CD34+ cells/kg

    Initial therapy requirements

    Initial coverage for SCD requires meeting all specified clinical and laboratory criteria.

    Refer to initial criteria: See 'Initial Therapy - Sickle Cell Disease' criteria set for specific requirements including diagnosis, genotype confirmation, age, VOE/transfusion history, hydroxyurea failure/intolerance, HSCT eligibility, specialist involvement, and minimum CD34+ cell dose.

    Initial therapy (SCD dosing)

    Dosing guidance provided for sickle cell disease

    SCD initial dosing: Minimum recommended dose for SCD: 3 × 10^6 CD34+ cells/kg IV.3 × 10^6 CD34+ cells/kg

    Appendix E specifies this as the minimum recommended dose for SCD.

    Appendix E: Safety and Product Parameters

    Safety-related conditions and dosing/product parameters included in appendices:

    Advanced liver disease examples: Patient has any of the listed advanced liver disease features (cirrhosis; bridging or significant fibrosis; active hepatitis; persistent AST, ALT, or direct bilirubin >3x ULN; baseline PT or PTT >1.5x ULN).

    These are examples of advanced liver disease noted in Appendix E; may inform eligibility or risk assessment.

    Dosing parameter for SCD: Minimum recommended dose for sickle cell disease: 3 × 10^6 CD34+ cells/kg IV.3 × 10^6 CD34+ cells/kg

    Listed as SCD minimum recommended dose in Appendix E.

    Product availability: Single-dose cell suspension: one to four infusion bags containing 1.7 to 20 × 10^6 cells/mL suspended in cryopreservation solution.1.7 to 20 × 10^6 cells/mL

    Product concentration and packaging details from Appendix E.

    Coverage is not authorized for indications that are not FDA‑approved and are not specifically addressed by this policy unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (for Medicaid, see CP.PMN.53) or the applicable evidence of coverage documents.

    The policy identifies examples of advanced liver disease to inform eligibility and risk assessment. Examples include, but are not limited to: cirrhosis; bridging or significant fibrosis; active hepatitis; persistent AST, ALT, or direct bilirubin values > 3x ULN; and baseline prothrombin time (PT) or partial thromboplastin time (PTT) > 1.5x ULN.

    Referenced diagnosis and procedure codes in this clinical policy are provided for informational purposes only; inclusion of a code does not guarantee coverage. Providers should verify current coding guidance and submit prior authorization requests and claims consistent with applicable billing rules and payer requirements.

    Initial Therapy Criteria

    Initial therapy requirements

    Initial coverage for SCD requires meeting all specified clinical and laboratory criteria.

    See coverage criteria: Refer to Initial Therapy - Sickle Cell Disease criteria set for specific requirements including genotype confirmation, age, VOE/transfusion history, hydroxyurea failure/intolerance, HSCT eligibility, specialist involvement, and minimum CD34+ cell dose.

    Initial therapy (SCD dosing)

    Dosing guidance provided for sickle cell disease

    SCD dosing guidance: Minimum recommended dose: 3 × 10^6 CD34+ cells/kg IV as specified for SCD in Appendix E.3 × 10^6 CD34+ cells/kg

    Continuation Therapy

    Continuation Therapy

    Lyfgenia is a single-administration gene therapy; ongoing maintenance dosing is not applicable.

    One-time dose only: Continued therapy will not be authorized as Lyfgenia is indicated to be dosed one time only.

    Approval duration: Not applicable

    Continuation

    No ongoing maintenance: Lyfgenia is a single-administration autologous gene therapy; ongoing maintenance or repeated dosing is not applicable.

    Coding and Product Parameters

    Referenced HCPCS CodesHCPCS
    J3394Injection, lovotibeglogene autotemcel, per treatment
    inv-08: Minimum CD34+ cell dose — 3 × 10^6 CD34+ cells/kg
    Minimum CD34+ cell dose3 × 10^6 CD34+ cells/kg (minimum recommended dose for SCD)
    ContextListed in Appendix E as SCD minimum recommended dose for dosing and administration
    RouteIntravenous administration (IV) as specified in dosing guidance
    inv-09: Liver enzyme / bilirubin thresholds — > 3x ULN for AST, ALT, or direct bilirubin
    Liver enzyme / bilirubin threshold> 3x ULN for AST, ALT, or direct bilirubin
    ContextListed as an example feature of advanced liver disease in Appendix E

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Prior authorization requires PDAC UM review

    Prior authorization for lovotibeglogene autotemcel (Lyfgenia) requires submission of clinical documentation and will be reviewed by the Precision Drug Action Committee (PDAC) Utilization Management process; providers must include documentation that all approval criteria are met.

    • Submit office chart notes, lab results, and other clinical information demonstrating the member meets all approval criteria.
    • Refer to CC.PHAR.21 for PDAC process details.
    Denial Risk

    PDAC Utilization Management review required

    All requests under this policy require PDAC Utilization Management Review; lack of PDAC approval may result in denial of the request.

    • PDAC review is mandatory for requests reviewed under this policy.

    Step Therapy Requirements

    StepRequirement
    1Documented failure or intolerance to hydroxyurea at any point in the past (per clinician judgement).

    Quantity Limits and Product Presentation

    inv-29: lovotibeglogene autotemcel (Lyfgenia) — one-time
    Quantity limit (course)One-time administration per lifetime (approval duration: one-time)
    Approval duration noteApproval duration listed as 12 months (one-time infusion per lifetime) in policy metadata
    Provider implicationNo continued dosing authorized — single administration only
    inv-30: lovotibeglogene autotemcel — one to four infusion bags per product (single-dose suspension)
    Packaging per productOne to four infusion bags per product (single-dose cell suspension)
    Concentration rangeEach bag contains 1.7 to 20 × 10^6 cells/mL suspended in cryopreservation solution

    Site of Care and Provider Qualifications

    Note

    Prescriber must be hematologist or transplant specialist

    Medication must be prescribed by or in consultation with a board‑certified hematologist or transplant specialist experienced in SCD; Lyfgenia is an HSCT‑based gene therapy typically administered in specialized transplant centers or hospital outpatient settings.

    • Ensure prescriber specialty and site-of-care capabilities are documented for the authorization request.
    Billing Rule

    Product is single‑dose suspension in 1–4 infusion bags

    Lyfgenia is supplied as a single‑dose cell suspension in one to four infusion bags (1.7 to 20 × 10^6 cells/mL) in cryopreservation solution; site-of-care planning must account for cryopreserved cell handling and specialized infusion capabilities.

    • Document facility capability for cryopreserved cell thawing, handling, and IV infusion.

    Background

    Lovotibeglogene autotemcel (Lyfgenia) is an autologous hematopoietic stem cell‑based gene therapy supplied as a single‑dose cell suspension (one to four infusion bags) intended for the treatment of patients with sickle cell disease. The product and appendices note dosing and safety parameters relevant to use, including minimum dose and product concentration ranges; clinicians should review the full prescribing information and product appendices when considering therapy.

    Definitions

    inv-22: VOE — Vaso-occlusive event (abbreviated VOE).
    DefinitionVaso-occlusive event (abbreviated VOE)
    AbbreviationVOE stands for vaso-occlusive event
    ContextUsed in eligibility criteria for SCD to quantify disease burden (e.g., ≥4 VOEs in 24 months)
    inv-23: HSCT — Hematopoietic stem cell transplantation.
    DefinitionHematopoietic stem cell transplantation
    AbbreviationHSCT stands for hematopoietic stem cell transplantation
    Context

    Coding Notes and References

    Referenced HCPCS CodesHCPCS
    J3394Injection, lovotibeglogene autotemcel, per treatment
    Policy Summary
    Payermeridian
    PolicyLovotibeglogene autotemcel (Lyfgenia) gene therapy coverage
    Policy CodePolicy MDN.CP.PHAR.627
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewJan 2, 2026
    Next Review Date
    Key ActionPrior authorization requires PDAC review and submission of clinical documentation that all approval criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for Lyfgenia (lovotibeglogene autotemcel)Initial Therapy CriteriaContinuation TherapyCoding and Product ParametersProvider Actions, Authorization, and DocumentationStep Therapy RequirementsQuantity Limits and Product PresentationSite of Care and Provider QualificationsBackgroundDefinitionsCoding Notes and References
    Clinical implication
    Persistent values exceeding this threshold may indicate advanced liver disease relevant to eligibility or risk assessment
    inv-10: Coagulation threshold — Baseline PT or PTT > 1.5x ULN
    Coagulation thresholdBaseline prothrombin time (PT) or partial thromboplastin time (PTT) > 1.5x ULN
    ContextIdentified in Appendix E as an example feature of advanced liver disease
    Clinical implicationElevated baseline PT/PTT above this threshold may affect eligibility or require further evaluation prior to HSCT-based gene therapy
    Billing Rule

    Billing code: use HCPCS J3394

    Claims and prior authorization submissions should reference HCPCS code J3394 (Injection, lovotibeglogene autotemcel, per treatment); inclusion of the code is informational and does not by itself guarantee coverage.

    • Use HCPCS J3394 when submitting claims for lovotibeglogene autotemcel.
    • Coding inclusion is informational—prior authorization and PDAC approval are still required.
    Note

    Consider listed therapeutic alternatives (e.g., hydroxyurea, Siklos)

    Therapeutic alternatives such as hydroxyurea and Siklos are listed in Appendix B and should be considered as part of the standard-of-care assessment prior to gene therapy.

    • Document prior use, failure, or intolerance to hydroxyurea if applicable.
    • Appendix B lists dosing regimens for hydroxyurea and Siklos as alternatives.
    Step Therapy

    No step therapy requirements specified

    This policy does not describe any step therapy requirements; no mandated step therapy is specified in the cited sections.

    • Documented failure or intolerance to hydroxyurea is an approval criterion but is not presented here as a formal step therapy protocol.
    Documentation Required

    Submit supporting clinical documentation with request

    Providers must submit supporting documentation (office chart notes, lab results, or other clinical information) showing the member meets all approval criteria when requesting authorization.

    • Include clinical notes, laboratory data, genetic test results, and prescriber attestations as applicable.
    Documentation Required

    Genetic testing and prescriber attestation required

    Include genetic testing confirming sickle cell disease (e.g., confirmed βS/βS genotype per Appendix D) and a prescriber attestation that the patient is clinically stable and eligible for HSCT and has prior treatment history (e.g., hydroxyurea failure/intolerance).

    • Provide genetic confirmation showing βS/βS genotype as applicable.
    • Prescriber must attest to HSCT eligibility and document hydroxyurea failure or intolerance if claimed.
    Documentation Required

    Reference prescribing information and cited literature

    Providers should reference and attach current Lyfgenia prescribing information and relevant cited literature (Appendix E references the Lyfgenia PI and key clinical studies) when documenting requests.

    • Include Lyfgenia Prescribing Information and pertinent clinical references cited in Appendix E as supporting documentation.
    Denial Risk

    Non‑FDA indications require off‑label documentation

    Coverage is not authorized for non‑FDA approved indications unless sufficient documentation per the off‑label use policies is provided; requests for non‑FDA indications without required off‑label documentation may be denied.

    • Follow off‑label use policy CP.PMN.53 (Medicaid) or other applicable off‑label policy and provide supporting evidence.
    Note

    Coding inclusion does not guarantee coverage

    Inclusion or exclusion of any codes in this clinical policy does not guarantee coverage; providers must reference the most up-to-date professional coding guidance prior to claim submission.

    • Coding listed in the policy is informational only and does not substitute for prior authorization or PDAC approval.
    Handling implicationSite-of-care must accommodate cryopreserved cell handling and infusion of multiple bags if supplied
    Lyfgenia is an HSCT-based autologous gene therapy; prescriber attestation of HSCT eligibility is required
    inv-24: Advanced liver disease — Advanced liver disease
    DefinitionAdvanced liver disease (examples include cirrhosis, bridging or significant fibrosis, active hepatitis)
    Laboratory examplesPersistent AST, ALT, or direct bilirubin > 3x ULN; baseline PT or PTT > 1.5x ULN
    Policy roleListed in Appendix E as examples to inform eligibility or risk assessment prior to therapy